Skip to main content
. 2022 Feb 2;150:e45. doi: 10.1017/S0950268822000152

Table 3.

Factors associated with RSV bronchiolitis severity

Variable Severe disease (N = 831) Less severe disease (N = 396)
N (%) N (%) OR (95% CI) P value
Residential SES
Low SES (1–4) 406 (48.9) 208 (52.9) 0.85 (0.67–1.08) 0.2
High SES (5–10) 424 (51.1) 185 (47.1) Reference
Sex
Male 494 (59.4) 211 (53.3) 1.28 (1.01–1.64) 0.04
Female 337 (40.6) 185 (46.7) Reference
Age, months df = 2 <0.001
0–5 501 (60.3) 285 (72.0) 0.46 (0.30–0.71) <0.001
6–11 216 (26.0) 81 (20.5) 0.70 (0.44–1.13) 0.1
12–23 114 (13.7) 30 (7.5) Reference
Gestational age at birth (weeks)
≤36 91 (14.4) 37 (12.9) 0.88 (0.59–1.33) 0.5
>36 543 (85.6) 250 (87.1) Reference
Chronic medical conditionsa 90 (10.8) 28 (7.1) 1.60 (1.03–2.48) 0.04
Chest X-ray
Pneumonia 527 (63.4) 162 (41.1) 2.48 (1.94–3.17) <0.001
No pneumoniab 304 (36.6) 232 (58.9) Reference
History of stay in neonatal intensive care at birtha 56 (9.2) 19 (5.5) 1.73 (1.01–2.97) 0.04
History of respiratory disordersa 25 (10.2) 2 (3.6) 3.01 (0.69–13.11) 0.1
Congenital malformationsa 28 (3.4) 11 (2.8) 1.22 (0.60–2.48) 0.6
Treatment with inhalations during hospitalisationa 714 (86.1) 320 (81.2) 1.44 (1.04–1.98) 0.03
Treatment with inhalations before hospitalisationa 302 (37.8) 114 (29.2) 1.47 (1.14–1.91) 0.003
Oxygen therapya 382 (47.7) 74 (19.1) 3.86 (2.89–5.15) <0.001
Steroid therapy during hospitalisationa 222 (27.4) 35 (9.0) 3.80 (2.60–5.56) <0.001
Steroid therapy before hospitalisationa 156 (19.5) 65 (16.5) 1.23 (0.89–1.69) 0.2
Vapotherm therapya 38 (6.5) 7 (2.1) 3.30 (1.46–7.47) 0.003

CI, confidence interval; OR, odds ratio; RSV, respiratory syncytial virus; SES, socio-economic status.

a

Reference category = not having the condition.

b

No pneumonia by chest X-ray or by clinical judgment (i.e. chest X-ray was not ordered).